FDA Approves Tarlatamab as First DLL3-Targeted Therapy for Small Cell Lung Cancer
Key Insights
Tarlatamab, a first-in-class DLL3 (search) T-cell engager, received FDA accelerated approval in May 2024 for treating relapsed/refractory small cell lung cancer (search), demonstrating a 40% objective response rate in clinical trials.
DLL3 (search) is expressed in approximately 80% of SCLC cells and has emerged as a promising therapeutic target, with multiple drug modalities including bispecific antibodies, ADCs, and CAR-T therapies in development.
While early DLL3 (search)-targeted ADCs showed limited success due to toxicity, newer bispecific and trispecific antibodies are showing encouraging results in clinical trials, potentially transforming SCLC treatment.
The FDA's accelerated approval of tarlatamab (Imdelltra) marks a significant breakthrough in the treatment of small cell lung cancer (search) (SCLC), offering new hope for patients with limited therapeutic options. This first-in-class DLL3 (search)-targeted T-cell engager represents a novel approach to treating this aggressive form of lung cancer.
Clinical Trial Results Lead to Approval
The approval was based on data from the DeLLphi-301 trial, which enrolled 222 patients with relapsed or refractory SCLC who had received at least two prior lines of therapy. In the pivotal study, patients receiving the approved 10mg dose showed an impressive 40% objective response rate, with 2% achieving complete responses. The majority of responding patients (59%) maintained their response for at least six months, with median progression-free survival reaching 4.9 months and overall survival extending to 14.3 months.
Mechanism of Action and Safety Profile
Tarlatamab functions by simultaneously binding to DLL3 (search) on cancer cells and CD3 on T cells, facilitating T-cell-mediated tumor cell destruction. The therapy employs a step-up dosing regimen to manage potential adverse effects, starting with 1mg on day one, followed by 10mg on days 8 and 15, and continuing every two weeks thereafter.
Cytokine release syndrome (CRS) emerged as the primary adverse event, affecting 51% of patients at the target dose, though most cases were grade 1 or 2. The treatment protocol includes careful monitoring and management strategies, with patients requiring 22-24 hours of observation during initial dosing.
Expanding Landscape of DLL3-Targeted Therapies
Beyond tarlatamab, several other DLL3 (search)-targeted approaches are under investigation:
- BI 764532: A bispecific antibody showing promising early results with a 26% response rate in SCLC patients
- PT217: A novel bispecific antibody targeting both DLL3 and CD47
- MK-6070: A trispecific antibody demonstrating encouraging preliminary efficacy
- CAR-T cell therapies: Several programs exploring cellular therapy approaches
Future Directions and Clinical Impact
Multiple clinical trials are investigating tarlatamab in various treatment settings, including:
- First-line therapy in combination with standard treatments
- Maintenance therapy following initial treatment
- Earlier stage disease
- Other DLL3-expressing cancers
The emergence of DLL3 (search)-targeted therapies represents a significant advancement in SCLC treatment, potentially offering new options for patients who historically have had limited therapeutic choices. Ongoing research continues to explore optimal patient selection, treatment sequencing, and combination strategies.